SEC Form 10-Q filed by Tarsus Pharmaceuticals Inc.
$TARS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | $19.00 | Neutral | Goldman |
| 7/18/2023 | $44.00 | Outperform | William Blair |
| 5/18/2023 | Buy | Guggenheim | |
| 8/1/2022 | $40.00 | Overweight | Barclays |
| 12/21/2021 | $40.00 | Buy | HC Wainwright & Co. |
| 11/23/2021 | $55.00 | Outperform | Oppenheimer |
| 10/8/2021 | $50.00 → $65.00 | Strong Buy | Raymond James |
| 6/29/2021 | $39.00 → $50.00 | Strong Buy | Raymond James |
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
3 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025 Management to host webcast on Tuesday, January 14, 2025, at 8:00 a.m. P.T. / 11:00 a.m. E.T. IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today provided an update on the Company's key priorities for 2025, including plans to advance TP-04 for the potential treatment of Ocular Rosacea, another category-creating opportunity in eye care. "2024 was a groundbreaking year for Tarsus as we established XDEMVY as one of the most successful eye ca
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across objective measures of Meibomian Gland Disease and important patient symptoms in Demodex blepharitis patients Management to host conference call today, November 13, 2024, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharm
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access
8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for 2H 2025 Management to host webcast on Tuesday, January 14, 2025, at 8:00 a.m. P.T. / 11:00 a.m. E.T. IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today provided an update on the Company's key priorities for 2025, including plans to advance TP-04 for the potential treatment of Ocular Rosacea, another category-creating opportunity in eye care. "2024 was a groundbreaking year for Tarsus as we established XDEMVY as one of the most successful eye ca
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining large Medicare contracts; broad commercial and Medicare coverage now extends to more than 80% of covered lives New XDEMVY data demonstrated statistically significant and clinically meaningful improvements from baseline across objective measures of Meibomian Gland Disease and important patient symptoms in Demodex blepharitis patients Management to host conference call today, November 13, 2024, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharm
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceutic
Goldman initiated coverage of Tarsus Pharmaceuticals with a rating of Neutral and set a new price target of $19.00
William Blair initiated coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $44.00
Guggenheim initiated coverage of Tarsus Pharmaceuticals with a rating of Buy
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access
IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. In this new role, she will be responsible for leading the strategy, direction and execution of the Company's new Medical Organization compris
IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests. Mr. Farrow is a seasoned finance and corporate strategy executive with more than two decades of experience successfully leading teams in the life science industry, including several publicly tra
SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)